Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
14 hedge funds and large institutions have $18.8M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
8% more funds holding
Funds holding: 13 → 14 (+1)
55% less capital invested
Capital invested by funds: $41.7M → $18.8M (-$22.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$377K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$203K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
+$87.8K |
| 4 |
DAM
DLD Asset Management
New York
|
+$76.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.13M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$320K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$132K |
| 4 |
SCM
Sio Capital Management
New York
|
-$103K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$17K |
AYLA Hedge Fund Activity: Q1 2022 in Review
14 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q1 2022, worth a combined $18.8M — down 55% from $41.7M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AYLA positions and 1 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $377K. The largest seller was Redmile Group, cutting an estimated $1.13M.
- 14 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q1 2022, up from 13 in Q4 2021.
- Funds reported $18.8M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 55% quarter-over-quarter.
- 2 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 1 closed out, a net change of +1 holder.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Millennium Management, an estimated $377K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Redmile Group, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2022.